← Back to Search

Dietary Supplement

AC-11 for Aging

Phase 2
Waitlist Available
Led By Phillip Gallegos
Research Sponsored by TruDiagnostic
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up change in epigenetic age from baseline to 6 months
Awards & highlights

Study Summary

This trial will study the effects of AC-11 on 24 patients over 6 months to see if it can reverse epigenetic markers of aging.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~change in epigenetic age from baseline to 6 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and change in epigenetic age from baseline to 6 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Methylation age clock testing
Telomere Test

Trial Design

1Treatment groups
Experimental Treatment
Group I: AC-11Experimental Treatment1 Intervention
6 months of treatment with AC-11

Find a Location

Who is running the clinical trial?

TruDiagnosticLead Sponsor
11 Previous Clinical Trials
454 Total Patients Enrolled
8 Trials studying Aging
344 Patients Enrolled for Aging
Optigenex, IncUNKNOWN
Phillip GallegosPrincipal InvestigatorThrive Medicine Clinic

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Who else is applying?

What state do they live in?
California
How old are they?
18 - 65
What portion of applicants met pre-screening criteria?
Did not meet criteria
~8 spots leftby Apr 2025